Clovis Oncology Sets New 52-Week Low at $35.86 (CLVS)
Clovis Oncology (NASDAQ:CLVS) shares hit a new 52-week low during mid-day trading on Thursday , Stock Ratings News reports. The company traded as low as $35.86 and last traded at $36.16, with a volume of 658,320 shares trading hands. The stock had previously closed at $37.30.
A number of analysts have recently weighed in on CLVS shares. Analysts at Stifel Nicolaus upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, June 5th. They now have a $50.00 price target on the stock. Finally, analysts at Goldman Sachs cut their price target on shares of Clovis Oncology from $85.00 to $50.00 in a research note on Wednesday, June 4th. They now have a “neutral” rating on the stock. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $75.38.
The stock’s 50-day moving average is $41.82 and its 200-day moving average is $60.25. The company’s market cap is $1.236 billion.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.91) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.85) by $0.06. The company had revenue of $13.60 million for the quarter. On average, analysts predict that Clovis Oncology will post $-3.84 earnings per share for the current fiscal year.
Clovis Oncology, Inc (NASDAQ:CLVS) is a Development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.